Ferrand Aurélie, Vergalli Julia, Pagès Jean-Marie, Davin-Regli Anne
UMR_MD1, U-1261, Aix-Marseille University, INSERM, SSA, IRBA, MCT, Faculté de Pharmacie, 27 Bd Jean Moulin, 13385 Marseille cedex05, France.
Microorganisms. 2020 Jun 1;8(6):833. doi: 10.3390/microorganisms8060833.
The transport of small molecules across membranes is a pivotal step for controlling the drug concentration into the bacterial cell and it efficiently contributes to the antibiotic susceptibility in . Two types of membrane transports, passive and active, usually represented by porins and efflux pumps, are involved in this process. Importantly, the expression of these transporters and channels are modulated by an armamentarium of tangled regulatory systems. Among them, Helix-turn-Helix (HTH) family regulators (including the AraC/XylS family) and the two-component systems (TCS) play a key role in bacterial adaptation to environmental stresses and can manage a decrease of porin expression associated with an increase of efflux transporters expression. In the present review, we highlight some recent genetic and functional studies that have substantially contributed to our better understanding of the sophisticated mechanisms controlling the transport of small solutes (antibiotics) across the membrane of . This information is discussed, taking into account the worrying context of clinical antibiotic resistance and fitness of bacterial pathogens. The localization and relevance of mutations identified in the respective regulation cascades in clinical resistant strains are discussed. The possible way to bypass the membrane/transport barriers is described in the perspective of developing new therapeutic targets to combat bacterial resistance.
小分子跨膜转运是控制药物进入细菌细胞浓度的关键步骤,它有效地影响了细菌对抗生素的敏感性。该过程涉及两种类型的膜转运,即被动转运和主动转运,通常分别由孔蛋白和外排泵来体现。重要的是,这些转运蛋白和通道的表达受到一系列复杂调控系统的调节。其中,螺旋-转角-螺旋(HTH)家族调节因子(包括AraC/XylS家族)和双组分系统(TCS)在细菌适应环境压力方面起着关键作用,并且能够调控与外排转运蛋白表达增加相关的孔蛋白表达降低。在本综述中,我们重点介绍了一些近期的遗传学和功能研究,这些研究极大地增进了我们对控制小溶质(抗生素)跨膜转运复杂机制的理解。结合临床抗生素耐药性和细菌病原体适应性这一令人担忧的背景,对这些信息进行了讨论。还讨论了临床耐药菌株中各自调控级联中鉴定出的突变的定位和相关性。从开发对抗细菌耐药性的新治疗靶点的角度,描述了绕过膜/转运屏障的可能途径。